Pentavalent antimonial

Pentavalent antimonial‏‎ is a type of antimonial compound that is used in the treatment of leishmaniasis, a disease caused by protozoan parasites of the genus Leishmania. These compounds are classified as chemotherapy agents and are also known as antimony-containing drugs.

History[edit | edit source]

The use of pentavalent antimonial compounds in the treatment of leishmaniasis dates back to the early 20th century. The first such compound, antimony potassium tartrate, was introduced in the 1920s. This was followed by the development of sodium stibogluconate and meglumine antimoniate in the 1940s and 1950s, respectively.

Mechanism of Action[edit | edit source]

Pentavalent antimonial compounds work by inhibiting the growth of Leishmania parasites. They are thought to do this by interfering with the parasites' metabolism, specifically by disrupting their ability to produce energy. However, the exact mechanism of action is not fully understood.

Side Effects[edit | edit source]

Like all chemotherapy agents, pentavalent antimonial compounds can cause side effects. These can include nausea, vomiting, diarrhea, and abdominal pain. In rare cases, they can also cause serious side effects such as cardiac arrhythmias and pancreatitis.

Resistance[edit | edit source]

Resistance to pentavalent antimonial compounds is a growing problem, particularly in regions where leishmaniasis is endemic. This is thought to be due to the overuse and misuse of these drugs. Efforts are currently underway to develop new treatments for leishmaniasis that are not based on antimony.